Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Nov 12, 2021 3:26pm
141 Views
Post# 34121238

RE:RE:What do we need- 35 patients?

RE:RE:What do we need- 35 patients?

PezDalatoYou wrote: I don't get the DIMI delay(s) for a number of reasons: 1. Dialysis sucks. As someone who has seen first hand what a dialysis clinic is like...a patient stuck in there would almost kill for a chance to get out and have their treatment at home. Finding 35 patients to volunteer should not be a problem. Taping a 'volunteers wanted' sign to the clinic door will move this forward faster. 2. A company like DaVi should be rolling out the red carpet and giving top priority to move the Dimi approval process forward...as a high corporate directive. It is in their own best interest. 3. Kellum knows all of this intimately. The remaining contents of the NR are just puzzle pieces ready to be placed, IMHO. Maybe the ease of where/when the DIMI trial can take place is the clue. ; - )


I like this post Pez and the last sentence. 

The failure to move either Trial forward SEEMS LIKE it MUST BE a big clue in and of itself. 

Maybe we need to ask, who & how someone benefits from stalling BOTH Trials, plus a delay on a spin off, plus a delay on laying the groundwork for US investor demand? 


Besides two Trials stalled, delayed or,  moving at a snails pace,  we have:

-Very little engagement with investment  community
-when done, it's done poorly at bad times with pretty much zero results 
- lowest level of US listing, no news flow
- US IR MIA
- plans to disclose US listing plans continue to be pushed ahead 
- the last two consecutive financings were supposed to have gone  to US institutions ( the first was supposed to be 11 "institutions", the second all taken up by AGP ) 
- no AGP Analyst Report yet 
- a Dialco spin-off has been MIA for > 1 year 
- dismissal or avoidance of the PMX for COVID discussion 
- Baxter seems to have a ROFR on PMX distribution with a competing/ complimentary? product
- Baxter has expressed an interest in the past in getting back into the HD market 
 

Before Gm dismisses this all as simply a lifestyle play , or gross mismgt. MAKE NO MISTAKE this is still a $2B to $5B opportunity AND THEY KNOW IT!

IMO it's time for Mgt to disclose the real plan/ endgame to ALL shareholders. 

Is it to be listed on Nasdaq with accompanying value discovery (share appreciation) over time? or NOT? 

The current set of circumstances and excuses no longer pass the smell test.

MM




 

<< Previous
Bullboard Posts
Next >>